Amunix Operating Inc.

Genencor International, Inc.

Amunix Pharmaceuticals, Inc

Danisco US Inc.

The Procter Gamble Company

Bioverativ Therapeutics Inc.

Other

Eli Lilly and Company

Life Technologies Corporation

Biotrove, Inc.

Biogen Ma Inc.

Volker Schellenberger

James T. Kellis

Christian Paech

Donald P. Naki

Chia-wei Wang

Willem P Stemmer

Joshua A Silverman

Nathan C Geething

Benjamin Spink

Katherine D Collier

Jeffrey L Cleland

James T Kellis, Jr

Robert Mark Caldwell

Joanne Nadherny

Donald P Naki

Ayrookaran J Poulose

Christian G Paech

Wayne To

Amy Deming Liu

Olga V Selifonova

Bee-Cheng Sim

Alfred Busch

Michael Stanford Showell

Chanchal Kumar Ghosh

Andreas Crameri

Mikhail Popkov

Nathaniel C Gordon

Judith A Fox

Andr&eacute; Cesar Baeck

Ryohei Ohtani

Michael D Scholle

Fan Yang

Vladimir Podust

Thomas B Morrison

Willem P C Stemmer

Robert T Peters

Haiyan Jiang

Fiona A Harding

John D Kulman

Tongyao Liu

M Harunur Rashid

Edwin Lee

Pei-yun Chang

Lance P Encell

Deping Wang

Andre Cesar Baeck

Aldis Darzins

Andrew Ihor Korytko

John Michael Beals

Ekta Seth Chhabra

Maria R Diaz-Torres

David Bruce Baldwin

Amy D Liu

Sheng Ding

Desiree Thayer

Chia-Wei Wang

Bryant McLaughlin

Eric Johansen

Nicholas Leiva

André Cesar Baeck

Darragh Maccann

Chen Gu

Adam C Kean

Martin Roberge

Rashid M Harunur

James T Kellis

Robert M Caldwell

Andre C Baeck

Baisong Mei

John Beaber

Garabet G Toby

Amy Deming Lui

Angela Henkensiefken

James Mcclory

Philipp Kuhn

Andre Frenzel

Mika Derynck

Bryan Irving

John Kulman

Lucas Liu

Milton To

Viktoriya Dubrovskaya

Chia-wel Wang

Ian M Brennan

George M Bright

Beat O Blattmann

John M Davis

Gregory T Mrachko

Fatbardha Varfaj

Andr&eacute;Cesar Baeck

Eric Humphriss

Nathan Carl Geething

Willem Peter Stemmer

Pei-Yun Chang

Bryant Mclaughlin

Susan E Alters

The disclosure describes antigen-binding molecules with binding specificity to cluster of differentiationT cell receptor (CD), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.

Compositions targeting prostate-specific membrane antigen and methods for making and using the same

Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.

HER-2 targeted bispecific compositions and methods for making and using the same

The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.

Extended recombinant polypeptides and compositions comprising same

The present invention relates to activatable recombinant polypeptide compositions comprising a cleavage release segment. In some instances, the activatable recombinant polypeptide compositions include an XTEN linked to binding moieties by cleavable release segments that, when cleaved, the binding moieties are capable of binding together effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable activatable recombinant compositions.

Release segments and binding compositions comprising same

The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

Chimeric polypeptide assembly and methods of making and using the same

The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.

XTEN conjugate compositions and methods of making same

The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.

Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same

The present invention provides chimeric proteins comprising a Factor VIII (FVIII) polypeptide and XTEN polypeptides. The FVIII polypeptide can have a reduced affinity for von Willebrand Factor (VWF). XTEN polypeptides of appropriate sizes are inserted into the FVIII polypeptide at particular locations in order to extend the half-life of the FVIII polypeptide. The invention also includes nucleotides, vectors, host cells, and methods of using the chimeric proteins, e.g., to treat bleeding diseases and disorders.

Factor VIII-XTEN fusions and uses thereof

The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.

Factor VIII compositions and methods of making and using same

A method for holding samples for analysis and an apparatus thereof includes a testing plate with a pair of opposing surfaces and a plurality of holes. Each of the holes extends from one of the opposing surfaces to the other one of the opposing surfaces. The holes are arranged in groups, where each group has at least two rows and two columns of holes. The groups are arranged in sets, where each set has at least two rows and two columns of groups. To analyze samples, at least one of the opposing surfaces of the testing plate is immersed in a solution to be analyzed. A portion of the solution enters openings for each of the holes in the immersed opposing surface. Once the holes are filled with solution, the testing plate is removed and is held above a supporting surface. Surface tension holds the solution in each of the holes. The solution in one or more of the holes is then analyzed and the solution in one of these holes is identified for further study. The location of the identified solution is marked based upon its location within a particular set and group of holes.

Multi-through hole testing plate for high throughput screening

The present invention relates to the field of medicine and the treatment of diabetes or hyperglycemia within that field. More particularly, the invention relates to a compound that lowers blood glucose, pharmaceutical compositions containing such a compound, and therapeutic uses of such a compound. The compound claimed herein comprises an A chain and a B chain, wherein the amino acid sequence of the A chain is SEQ ID NO: 1 and the amino acid sequence of the B chain is SEQ ID NO: 2.

Blood glucose lowering compound

The present invention relates to compositions comprising glucose regulating peptides linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of glucose regulating peptide-related diseases, disorders, and conditions.

Glucose-regulating polypeptides and methods of making and using same

Growing community of inventors

Palo Alto, CA, United States of America

Volker Schellenberger